Novel therapies for hypereosinophilic syndromes.
BACKGROUND
Conventional therapies (corticosteroids, cytotoxic agents or interferon-a) or newer compounds such imatinib are used specifically in subsets of hypereosinophilic syndromes (HES). However other therapies are still needed in this condition.


OBJECTIVE
To review the novel therapies for HES discussing their advantages and shortcomings.


RESULTS
Preclinical and clinical data on novel tyrosine kinase inhibitors, anti-IL -5 antibodies or anti-CD52 antibodies (alemtuzumab) are analysed. The former might represent appropriate options in case of imatinib resistance; the efficacy of anti-IL-5 monoclonal antibodies therapy is limited by the occurrence of rebound eosinophilia and alemtuzumab might be a promising anti-eosinophil therapy for all HES subsets.


CONCLUSIONS
Some of the novel therapies might become appropriate therapeutic options for HES.
Antoniu
S A
SA
Division of Pulmonary Disease, University of Medicine and Pharmacy Gr.T.Popa, Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001557:Benzenesulfonates / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D000074301:CD52 Antigen; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000628:therapy; D000068877:Imatinib Mesylate; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D015848:Interleukin-5 / Q000037:antagonists & inhibitors / Q000276:immunology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D000077157:Sorafenib
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D001549:Benzamides; D001557:Benzenesulfonates; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D007155:Immunologic Factors; D016898:Interferon-alpha; D015848:Interleukin-5; D010671:Phenylurea Compounds; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D009536:Niacinamide; D000074323:Alemtuzumab; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases